MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02370nam a22003497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220706s20222022 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1473-7140 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1080/14737140.2022.2072300 [doi] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
35483033 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. |
| 251 ## - Source |
|---|
| Source |
Expert Review of Anticancer Therapy. :1-10, 2022 Jun 08 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Expert Rev Anticancer Ther. :1-10, 2022 Jun 08 |
| 253 ## - Journal Name |
|---|
| Journal name |
Expert review of anticancer therapy |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2022 Jun 08 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2022-07-06 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AREAS COVERED: We provide an overview of efforts to develop an adjuvant therapy in patients with high-risk RCC. This includes a critical review of efficacy, toxicity, and clinical implications from a large phase III trial leading to the FDA and EMA approvals of adjuvant pembrolizumab. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
EXPERT OPINION: Pembrolizumab offers an effective and well-tolerated adjuvant therapy for patients with surgically resected RCC at high-risk of disease recurrence. Future research will focus on optimal patient selection and biomarkers that predict benefit and/or toxicity from therapy. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
INTRODUCTION: Many patients with renal cell carcinoma (RCC) who undergo surgery with curative intent have a high risk of disease recurrence and until recently no palatable adjuvant systemic therapy options. Blocking the programmed death ligand (PD-1) immune checkpoint pathway with pembrolizumab has robust clinical efficacy in patients with metastatic RCC. Results from the KEYNOTE 564 trial demonstrate that adjuvant pembrolizumab significantly improves disease- free survival after nephrectomy or metastasectomy. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Hematology & Oncology Fellowship |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Georgetown University Hospital/MedStar Washington Hospital Center |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Serzan, Michael |
| Institution Code |
MedStar Georgetown University Hospital/MedStar Washington Hospital Center |
| Program |
Hematology & Oncology Fellowship |
| 790 ## - Authors |
|---|
| All authors |
Atkins MB, Serzan M |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1080/14737140.2022.2072300">https://dx.doi.org/10.1080/14737140.2022.2072300</a> |
| Public note |
https://dx.doi.org/10.1080/14737140.2022.2072300 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
